Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Oct

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

OptiTROP-Lung06 A Potential Alternative to Chemotherapy in Advanced PD-L1–Negative NSCLC?

How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation

Selpercatinib Sacituzumab Govitecan Show Activity in Thyroid Cancer Subtypes

ASTRO Updates Guideline on Shorter-Course Radiation Therapy for Localized Prostate Cancer

High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery